secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2021-09-07T23:59:59+00:00
Accession:  0001193125-21-265999
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO appoints Dr. Jean Bennett and George Migausky to Board; Luke Beshar resigns
--------------------------------------------------------------------------------

- Luke M. Beshar resigned from REGENXBIO Board effective September 3, 2021.
- Dr. Jean Bennett (gene therapy pioneer, co-founder of Spark Therapeutics) elected Class II director.
- George Migausky (former CFO of Dyax) elected Class III director and Audit Committee member.
- Each new director received option for 20,000 shares at $34.98, plus annual retainer.
- Dr. Bennett will serve on Nominating and Corp Gov Committee; Mr. Migausky on Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/d194596d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-265999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer